NysnoBio Awarded Michael J. Fox Foundation Grant for Advancement of Parkin Gene Therapy to IND

UF Innovate Accelerate client, NysnoBio, is pleased to announce additional funding from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to advance their Parkin gene therapy development candidate towards an investigational new drug (IND) status. This funding will support product manufacturing to enable the IND safety studies in preparation for human clinical trials.

Potential Impacts for Parkinson’s Disease (PD) Diagnosis and Treatment

Parkin-PD is the most potent known genetic form of PD, with almost 100% penetrance. In addition, the patients affected are typically younger than 35 years old, with significant disability in the prime years of their life. This therapy has the potential to restore dopaminergic function alleviating the movement disorder for these patients and restoring a high quality of life.

Learn more about NysnoBio Awarded Michael J. Fox Foundation Grant for Advancement of Parkin Gene Therapy to Ind